How Veligrotug Works: The Science Behind the New Thyroid Eye Disease (TED) Treatment

Bulging eyes. Double vision. Pain that gets worse just from looking sideways. Thyroid Eye Disease (TED) has been notoriously hard to treat at its actual cause — until now. In June 2026, the FDA approved veligrotug (Lumvoa) — a new IGF-1R-blocking antibody that goes after the disease mechanism itself, not just the downstream damage. In this video, we break down exactly how it works at the receptor level, walk through the THRIVE and THRIVE-2 trial data that got it approved, and cover the side effects and monitoring you need to know about Disclaimer: This YouTube channel is not intended to provide diagnosis, treatment, or medical advice. The content provided in this video is for informational purposes only. This should not be considered as a substitute for healthcare professional advice. Please consult a physician or other healthcare professional regarding any medical or health-related diagnosis or treatment options. The statements about specific products are not to diagnose, treat, cure, or prevent disease. References 1. https://www.ophthalmologytimes.com/vi... 2. https://www.medcentral.com/ophthalmol... 3. https://www.ophthalmologyadvisor.com/... 4. L Bartalena, G J Kahaly, L Baldeschi, C M Dayan, A Eckstein, C Marcocci, M Marinò, B Vaidya, W M Wiersinga, EUGOGO, The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy, European Journal of Endocrinology, Volume 185, Issue 4, Oct 2021, Pages G43–G67, https://doi.org/10.1530/EJE-21-0479 5. Ciarmatori, N., Quaranta Leoni, F., & Quaranta Leoni, F. M. (2025). Redefining treatment paradigms in thyroid eye disease: current and future therapeutic strategies. Journal of Clinical Medicine, 14(15), 5528. 6. Kaplan, R., Zhao, Y., Tsai, J., Dickinson, B., Swanson, T., Foster, K., & Bedian, V. (2025, December). Preclinical pharmacology, pharmacokinetics, and pharmacodynamics of veligrotug, a full antagonist antibody to the IGF-1 receptor in development for thyroid eye disease. In Mabs (Vol. 17, No. 1, p. 2585616). Taylor & Francis. 7. Yen, M. T., Cockerham, K., Saeed, P., Leibowitz, S., Mudumbai, R. C., Schittkowski, M. P., ... & Tamhankar, M. (2026). THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. Ophthalmology. 8. Rodien, P., Schittkowski, M., Konuk, O., Eckstein, A., Csutak, A., Eade, E., ... & Hermosilla, A. M. G. (2025, May). THRIVE-2 phase 3 trial of Veligrotug (VRDN-001) in chronic thyroid eye disease (TED): Efficacy and safety at 15 weeks. In Endocrine Abstracts (Vol. 110). Bioscientifica. #ThyroidEyeDisease #TED #Veligrotug #Lumvoa #GravesDisease #GravesOrbitopathy #Teprotumumab #Tepezza #IGF1R #TSHR #Proptosis #Diplopia #Endocrinology #Ophthalmology #FDAApproval #ThyroidHealth #EyeHealth #MedicalEducation #PharmacyEducation #ClinicalTrials #AutoimmuneDisease #Pharmacology #PharmacologyMadeEasy